Click here to get full coverage on ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Zacks Investment Research

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal  Zacks Investment Research

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Zacks Investment Research

Click here to get full coverage on Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results - simplywall.st

Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results  simplywall.st

Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results - simplywall.st

Click here to get full coverage on Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment - Yahoo Finance UK

TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment  Yahoo Finance UK

TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment - Yahoo Finance UK

Click here to get full coverage on What to do if you’re stuck in ALKS - 2025 Big Picture & Safe Entry Momentum Tips - newser.com

What to do if you’re stuck in ALKS - 2025 Big Picture & Safe Entry Momentum Tips  newser.com

What to do if you’re stuck in ALKS - 2025 Big Picture & Safe Entry Momentum Tips - newser.com

Click here to get full coverage on Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - Seeking Alpha

Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid  Seeking Alpha

Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - Seeking Alpha

Click here to get full coverage on Alkermes plc (Nasdaq: ALKS) boosts Avadel bid to $22.50 per share, expected 2026 close - Stock Titan

Alkermes plc (Nasdaq: ALKS) boosts Avadel bid to $22.50 per share, expected 2026 close  Stock Titan

Alkermes plc (Nasdaq: ALKS) boosts Avadel bid to $22.50 per share, expected 2026 close - Stock Titan

Click here to get full coverage on Truist Securities Raises Price Target for ALKS to $55.00, Mainta - GuruFocus

Truist Securities Raises Price Target for ALKS to $55.00, Mainta  GuruFocus

Truist Securities Raises Price Target for ALKS to $55.00, Mainta - GuruFocus

Click here to get full coverage on ALKS: NT2 study data support flexible orexin dosing, robust safety, and strategic market expansion - TradingView

ALKS: NT2 study data support flexible orexin dosing, robust safety, and strategic market expansion  TradingView

ALKS: NT2 study data support flexible orexin dosing, robust safety, and strategic market expansion - TradingView

Click here to get full coverage on Is ALKS stock bottoming out - Profit Target & Fast Gain Swing Trade Alerts - newser.com

Is ALKS stock bottoming out - Profit Target & Fast Gain Swing Trade Alerts  newser.com

Is ALKS stock bottoming out - Profit Target & Fast Gain Swing Trade Alerts - newser.com

Click here to get full coverage on Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates  Yahoo Finance

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on Alkermes (ALKS) Faces Potential Termination of Acquisition Agree - GuruFocus

Alkermes (ALKS) Faces Potential Termination of Acquisition Agree  GuruFocus

Alkermes (ALKS) Faces Potential Termination of Acquisition Agree - GuruFocus

Click here to get full coverage on Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PR Newswire

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025  PR Newswire

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PR Newswire

Click here to get full coverage on Will ALKS stock continue dividend increases - Analyst Upgrade & Weekly Return Optimization Plans - newser.com

Will ALKS stock continue dividend increases - Analyst Upgrade & Weekly Return Optimization Plans  newser.com

Will ALKS stock continue dividend increases - Analyst Upgrade & Weekly Return Optimization Plans - newser.com

Click here to get full coverage on ALKS or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance

ALKS or ILMN: Which Is the Better Value Stock Right Now?  Yahoo Finance

ALKS or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance

Click here to get full coverage on Alkermes (ALKS) Ups Acquisition Offer for Avadel Pharmaceuticals - GuruFocus

Alkermes (ALKS) Ups Acquisition Offer for Avadel Pharmaceuticals  GuruFocus

Alkermes (ALKS) Ups Acquisition Offer for Avadel Pharmaceuticals - GuruFocus

Click here to get full coverage on How to integrate ALKS into portfolio analysis tools - 2025 Price Targets & Free Technical Confirmation Trade Alerts - newser.com

How to integrate ALKS into portfolio analysis tools - 2025 Price Targets & Free Technical Confirmation Trade Alerts  newser.com

How to integrate ALKS into portfolio analysis tools - 2025 Price Targets & Free Technical Confirmation Trade Alerts - newser.com

Click here to get full coverage on Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say  Yahoo Finance

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Click here to get full coverage on Alkermes (ALKS) Increases Buyout Offer for Avadel Pharmaceuticals (AVDL) - GuruFocus

Alkermes (ALKS) Increases Buyout Offer for Avadel Pharmaceuticals (AVDL)  GuruFocus

Alkermes (ALKS) Increases Buyout Offer for Avadel Pharmaceuticals (AVDL) - GuruFocus

Click here to get full coverage on Sector ETF performance correlation with ALKS - 2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com

Sector ETF performance correlation with ALKS - 2025 Growth vs Value & Daily Volume Surge Trade Alerts  newser.com

Sector ETF performance correlation with ALKS - 2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com

Click here to get full coverage on Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports Second Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result - Yahoo Finance

Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result  Yahoo Finance

Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result - Yahoo Finance

Click here to get full coverage on Will Analyst Skepticism on Alixorexton Reshape Alkermes' (ALKS) Competitive Strategy in Narcolepsy? - simplywall.st

Will Analyst Skepticism on Alixorexton Reshape Alkermes' (ALKS) Competitive Strategy in Narcolepsy?  simplywall.st

Will Analyst Skepticism on Alixorexton Reshape Alkermes' (ALKS) Competitive Strategy in Narcolepsy? - simplywall.st

Click here to get full coverage on How to integrate ALKS into portfolio analysis tools - Dividend Hike & Safe Capital Growth Plans - newser.com

How to integrate ALKS into portfolio analysis tools - Dividend Hike & Safe Capital Growth Plans  newser.com

How to integrate ALKS into portfolio analysis tools - Dividend Hike & Safe Capital Growth Plans - newser.com

Click here to get full coverage on How to integrate ALKS into portfolio analysis tools - Portfolio Performance Report & Verified Chart Pattern Signals - newser.com

How to integrate ALKS into portfolio analysis tools - Portfolio Performance Report & Verified Chart Pattern Signals  newser.com

How to integrate ALKS into portfolio analysis tools - Portfolio Performance Report & Verified Chart Pattern Signals - newser.com

Click here to get full coverage on Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PR Newswire

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia  PR Newswire

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PR Newswire

Click here to get full coverage on What to do if you’re stuck in ALKS - 2025 Performance Recap & Comprehensive Market Scan Insights - newser.com

What to do if you’re stuck in ALKS - 2025 Performance Recap & Comprehensive Market Scan Insights  newser.com

What to do if you’re stuck in ALKS - 2025 Performance Recap & Comprehensive Market Scan Insights - newser.com

Click here to get full coverage on Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Click here to get full coverage on Avadel shares jump as Alkermes raises buyout bid - TradingView

Avadel shares jump as Alkermes raises buyout bid  TradingView

Avadel shares jump as Alkermes raises buyout bid - TradingView

Click here to get full coverage on Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study - Neurology Live

Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study  Neurology Live

Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study - Neurology Live

Click here to get full coverage on $ALKS stock is down 18% today. Here's what we see in our data. - Quiver Quantitative

$ALKS stock is down 18% today. Here's what we see in our data.  Quiver Quantitative

$ALKS stock is down 18% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025  PR Newswire

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire

Click here to get full coverage on What to do if you’re stuck in ALKS - Quarterly Portfolio Report & Community Supported Trade Ideas - newser.com

What to do if you’re stuck in ALKS - Quarterly Portfolio Report & Community Supported Trade Ideas  newser.com

What to do if you’re stuck in ALKS - Quarterly Portfolio Report & Community Supported Trade Ideas - newser.com

Click here to get full coverage on Alkermes (NASDAQ: ALKS) notes Avadel must give 5 Business Days’ notice, negotiate - Stock Titan

Alkermes (NASDAQ: ALKS) notes Avadel must give 5 Business Days’ notice, negotiate  Stock Titan

Alkermes (NASDAQ: ALKS) notes Avadel must give 5 Business Days’ notice, negotiate - Stock Titan

Click here to get full coverage on Trading Systems Reacting to (ALKS) Volatility - news.stocktradersdaily.com

Trading Systems Reacting to (ALKS) Volatility  news.stocktradersdaily.com

Trading Systems Reacting to (ALKS) Volatility - news.stocktradersdaily.com

Click here to get full coverage on Alkermes Appoints Joshua Reed as Chief Financial Officer - PR Newswire

Alkermes Appoints Joshua Reed as Chief Financial Officer  PR Newswire

Alkermes Appoints Joshua Reed as Chief Financial Officer - PR Newswire

Click here to get full coverage on Alkermes (ALKS) Shares Decline Amid Market Activity - GuruFocus

Alkermes (ALKS) Shares Decline Amid Market Activity  GuruFocus

Alkermes (ALKS) Shares Decline Amid Market Activity - GuruFocus

Click here to get full coverage on Alkermes plc Reports First Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports First Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports First Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Brigita Anna Alks Obituary August 8, 2025 - Lombardo Funeral Home

Brigita Anna Alks Obituary August 8, 2025  Lombardo Funeral Home

Brigita Anna Alks Obituary August 8, 2025 - Lombardo Funeral Home

Click here to get full coverage on Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1  PR Newswire

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Click here to get full coverage on Alkermes (ALKS) Positioned for Strategic Acquisition - GuruFocus

Alkermes (ALKS) Positioned for Strategic Acquisition  GuruFocus

Alkermes (ALKS) Positioned for Strategic Acquisition - GuruFocus

Click here to get full coverage on Alkermes (ALKS) Stock Experiences Notable Decline - GuruFocus

Alkermes (ALKS) Stock Experiences Notable Decline  GuruFocus

Alkermes (ALKS) Stock Experiences Notable Decline - GuruFocus

Click here to get full coverage on Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts - Yahoo Finance

Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts  Yahoo Finance

Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts - Yahoo Finance

Click here to get full coverage on Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo Finance

Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion  Yahoo Finance

Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo Finance

Click here to get full coverage on Alkermes (ALKS) Evaluates Options Following Avadel Pharmaceutica - GuruFocus

Alkermes (ALKS) Evaluates Options Following Avadel Pharmaceutica  GuruFocus

Alkermes (ALKS) Evaluates Options Following Avadel Pharmaceutica - GuruFocus

Click here to get full coverage on Alkermes (ALKS) Is Up 7.1% After Analyst Upgrades and Promising Sleep Disorder Data Release – Has The Bull Case Changed? - Sahm

Alkermes (ALKS) Is Up 7.1% After Analyst Upgrades and Promising Sleep Disorder Data Release – Has The Bull Case Changed?  Sahm

Alkermes (ALKS) Is Up 7.1% After Analyst Upgrades and Promising Sleep Disorder Data Release – Has The Bull Case Changed? - Sahm

Click here to get full coverage on Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? - Zacks Investment Research

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?  Zacks Investment Research

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? - Zacks Investment Research

Click here to get full coverage on Truist Financial Maintains Alkermes(ALKS.US) With Buy Rating, Raises Target Price to $55 - 富途牛牛

Truist Financial Maintains Alkermes(ALKS.US) With Buy Rating, Raises Target Price to $55  富途牛牛

Truist Financial Maintains Alkermes(ALKS.US) With Buy Rating, Raises Target Price to $55 - 富途牛牛

Click here to get full coverage on Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal - TradingView

Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal  TradingView

Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal - TradingView

Click here to get full coverage on Alkermes (ALKS) Margin Decline to 22.2% Challenges Bullish Narratives Despite Value Appeal - Sahm

Alkermes (ALKS) Margin Decline to 22.2% Challenges Bullish Narratives Despite Value Appeal  Sahm

Alkermes (ALKS) Margin Decline to 22.2% Challenges Bullish Narratives Despite Value Appeal - Sahm

Click here to get full coverage on Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia - Neurology Live

Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia  Neurology Live

Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia - Neurology Live

Click here to get full coverage on Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PR Newswire

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc  PR Newswire

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PR Newswire

Click here to get full coverage on Avadel Board Of Directors Declares Lundbeck Proposal A “Company Superior Proposal” - TradingView

Avadel Board Of Directors Declares Lundbeck Proposal A “Company Superior Proposal”  TradingView

Avadel Board Of Directors Declares Lundbeck Proposal A “Company Superior Proposal” - TradingView

Click here to get full coverage on Alkermes falls after mid-stage trial data for sleep therapy - Seeking Alpha

Alkermes falls after mid-stage trial data for sleep therapy  Seeking Alpha

Alkermes falls after mid-stage trial data for sleep therapy - Seeking Alpha

Click here to get full coverage on Alkermes (Nasdaq: ALKS) to join Stifel, Jefferies conferences; webcasts archived 14 days - Stock Titan

Alkermes (Nasdaq: ALKS) to join Stifel, Jefferies conferences; webcasts archived 14 days  Stock Titan

Alkermes (Nasdaq: ALKS) to join Stifel, Jefferies conferences; webcasts archived 14 days - Stock Titan

Click here to get full coverage on Are Medical Stocks Lagging Alkermes (ALKS) This Year? - Yahoo Finance

Are Medical Stocks Lagging Alkermes (ALKS) This Year?  Yahoo Finance

Are Medical Stocks Lagging Alkermes (ALKS) This Year? - Yahoo Finance

Click here to get full coverage on Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?  Yahoo Finance

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Click here to get full coverage on Why retail investors pile into ALKS stock - GDP Growth & Pattern Based Trade Signal System - newser.com

Why retail investors pile into ALKS stock - GDP Growth & Pattern Based Trade Signal System  newser.com

Why retail investors pile into ALKS stock - GDP Growth & Pattern Based Trade Signal System - newser.com

Click here to get full coverage on Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD - Neurology Live

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD  Neurology Live

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD - Neurology Live

Click here to get full coverage on Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN

Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid  MSN

Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN

Click here to get full coverage on ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study  Yahoo Finance

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance

Click here to get full coverage on Alkermes Advances in Sleep Disorder Treatment with ALKS 2680 Study - TipRanks

Alkermes Advances in Sleep Disorder Treatment with ALKS 2680 Study  TipRanks

Alkermes Advances in Sleep Disorder Treatment with ALKS 2680 Study - TipRanks

Click here to get full coverage on Wells Fargo Lowers Price Target for Alkermes (ALKS) to $37 | ALKS Stock News - GuruFocus

Wells Fargo Lowers Price Target for Alkermes (ALKS) to $37 | ALKS Stock News  GuruFocus

Wells Fargo Lowers Price Target for Alkermes (ALKS) to $37 | ALKS Stock News - GuruFocus

Click here to get full coverage on Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge  MSN

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN

Click here to get full coverage on Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 - PR Newswire

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025  PR Newswire

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 - PR Newswire

Click here to get full coverage on Alkermes (ALKS) Reports Positive Phase 2 Results for Narcolepsy Treatment - GuruFocus

Alkermes (ALKS) Reports Positive Phase 2 Results for Narcolepsy Treatment  GuruFocus

Alkermes (ALKS) Reports Positive Phase 2 Results for Narcolepsy Treatment - GuruFocus

Click here to get full coverage on Alkermes stock rating reiterated at Neutral by H.C. Wainwright - Investing.com UK

Alkermes stock rating reiterated at Neutral by H.C. Wainwright  Investing.com UK

ALKS

Price Chart

Key Statistics

Technicals

About ALKS

Latest News

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Zacks Investment Research

Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results - simplywall.st

Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Advanced Charts

Top Gainers

Top Losers